Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13

11 octobre 2017

07:00
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeuratm long-term, continuous drug...


10 octobre 2017

17:00
CHICAGO, Oct. 10, 2017 /PRNewswire/ -- Brain Research Foundation (BRF) will bestow its 2017 Frederic A. Gibbs award to a Chicago couple dedicated to the support and growth of innovative neuroscience research, and a financial company whose...

15:25
SAN FRANCISCO, Oct. 10, 2017 /PRNewswire/ -- Data from a prospective study on novel DotLab endometriosis biomarkers will be presented at the 2017 American Society of Reproductive Medicine (ASRM) Scientific Congress and Expo. The scientific abstract,...

14:10
SAN DIEGO, Oct. 10, 2017 /PRNewswire/ -- Biotheranostics today announced publication in the Clinical Cancer Research journal  of a study evaluating performance of a  Breast Cancer Index (BCI) that was specifically developed for early-stage, ER+...

13:59
-- Results from a 12-country survey of more than 75,000 patients shows limited patient awareness about cataract disease and available treatment options -- New findings presented at the XXXV European Society of Cataract & Refractive Surgeons (ESCRS)...

10:49
Study Shows Successful Delivery in Brain Cancer Patients and Reassuring Safety Profile TORONTO and HOUSTON, TX, Oct. 10, 2017 /PRNewswire/ - Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX "MDNA"), a clinical stage...

10:24
LAS VEGAS, Oct. 10, 2017 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) has entered into a Contract Research Agreement with the Universidad de Sevilla ("USE") to develop a time-released version of GB Sciences' proprietary, THC-free, myrcene-based...

09:53
MINNETONKA, Minn., Oct. 10, 2017 /PRNewswire/ -- Respicardia, Inc., a private medical technology company, announced today that it received U.S. Food and Drug Administration (FDA) approval of its remed?® System, a transvenous implantable...

09:00
PRAGUE, October 10, 2017 /PRNewswire/ -- Treatment with Ped-PRM significantly improved total sleep time (TST), sleep initiation and maintenance  Parents' quality of life and satisfaction from children's sleep increased significantly  ...

08:37
SAN DIEGO, Oct. 10, 2017 /PRNewswire/ -- Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of dosing in a Phase 1b study to evaluate the effects of ABX-1431, a first-in-class investigational monoacylglycerol...

08:30
MADRID, October 10, 2017 /PRNewswire/ -- PharmaMar (MCE: PHM) will present the final efficacy and safety data obtained from the Phase I/II trial combining PM1183 (lurbinectedin) with doxorubicin in relapsed small-cell lung cancer during a 'Research...

08:30
NOVATO, California, TOKYO and LONDON, October 10, 2017 /PRNewswire/ -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin Co.,...

08:00
SAN DIEGO, Oct. 10, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that it has initiated its phase 2b registration directed...

08:00
EXTON, Pa., Oct. 10, 2017 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today shared the results of a study highlighting the benefits of West's ID Adapter...

08:00
TOKYO and BOTHELL, Wash., Oct. 10, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Seattle Genetics Inc., (NASDAQ: SGEN) today announced dosing of the first patient in EV-201, a...

07:46
Le docteur Achille Gaspardone a présenté le registre de données italiennes/suédoises pour le système d'occlusion de FOP à base de sutures HeartStitch ® FRANCFORT, Allemagne, 10 octobre 2017 /PRNewswire/ -- Le professeur Achille Gaspardone,...

07:30
LEXINGTON, Mass., Oct. 10, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related...

07:01
NEW YORK, Oct. 10, 2017 /PRNewswire-USNewswire/ -- The National Multiple Sclerosis Society has committed nearly $14 million to support 40 new MS research projects. These are part of a comprehensive approach to accelerate research breakthroughs aimed...

07:00
KIRKLAND, QC, Oct. 10, 2017 /CNW/ - Ortho Regenerative Technologies Inc. ("Ortho RTi" or the "Corporation"), an emerging Orthopaedic and Sports Medicine Technology company, will begin trading today on the Canadian Securities Exchange ("CSE") under...

06:45
INDIANAPOLIS, Oct. 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 JUNIPER study evaluating Verzeniotm (abemaciclib), a cyclin-dependent kinase (CDK)4 and CDK6 inhibitor, as monotherapy in KRAS-mutated,...

05:00
Dr. Achille Gaspardone Presented The Italian/Swedish Data Registry For HeartStitch ® 's PFO Suture Based Closure System FRANKFURT, Germany, Oct. 10, 2017 /PRNewswire/ -- Prof. Dr. Achille Gaspardone, Director of Cardiology at Hospital of...


9 octobre 2017

19:01
BASEL, Switzerland, October 10, 2017 /PRNewswire/ -- Mundipharma EDO GmbH (EDO) has begun a US Phase 1/2 clinical study for tinostamustine (EDO-S101) in patients with advanced solid tumors at Stanford University, Cedars Sinai Medical Center (Los...

16:56
NEW YORK, Oct. 9, 2017 /PRNewswire/ -- ThyroSeq®, a joint partnership between UPMC and CBLPath, announced today, that the results of a double-blind, multi-center international study, validating the performance of ThyroSeq V3® in thyroid nodules with...

16:05
HILDEN and ROSTOCK, Germany and GERMANTOWN, Maryland, October 9, 2017 /PRNewswire/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and CENTOGENE AG today announced a collaboration and co-marketing agreement to provide customers more complete...

16:00
THOUSAND OAKS, Calif., Oct. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Prolia® (denosumab) for the...

15:31
ROME, Oct. 9, 2017 /PRNewswire/ -- Prof. Dr. Achille Gaspardone, Director of Cardiology at Hospital of Sant'Eugenio (Rome, Italy) presented a comprehensive report on closure of PFO (Patent Foramen Ovale) and related Atrial Septal Defect...

14:04
SANTA CLARA, Calif., Oct. 9, 2017 /PRNewswire/ -- Frost & Sullivan, the growth partnership company, announced today that it will host a live, complimentary Growth Innovation Leadership (GIL) briefing titled, "Microbiome: Revisiting the Micro and...

13:32
SANTA BARBARA, Calif., Oct. 9, 2017 /PRNewswire/ -- Evolus, Inc. (www.Evolus.com) today announced presentations of the data from the Phase II and III clinical trials of its investigational prabotulinumtoxinA 900 kilodalton (kDa) neuromodulator at The...

10:00
ELLICOTT CITY, Md., Oct. 9, 2017 /PRNewswire/ -- The Society for Clinical Research Sites (SCRS) announced to over 900 attendees at its 2017 Global Site Solutions Summit that Eli Lilly is the winning sponsor of the 2017 Sponsor Eagle Award, and INC...

09:05
PALO ALTO, Calif., Oct. 9, 2017 /PRNewswire/ -- AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm® Tissue Expander System, today announced that...

08:30
DUBLIN, Oct. 9, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that positive new data from multiple studies of VIBATIV® (telavancin) were presented at IDWeektm 2017, which was...

08:30
BOCA RATON, Fla., Oct. 9, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and keloids with Superficial Radiation Therapy (SRT), announced today that an...

08:00
SAN DIEGO, Oct. 9, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) granted an orphan drug designation to PCM-075 for the treatment of...

08:00
EXTON, Pennsylvania, Oct. 9, 2017 /PRNewswire/ --Essential Medical, Inc. today announced initiation of enrollment in a post market clinical registry in the regions where MANTAtm is commercially available.  Principle...

08:00
SAN DIEGO, Oct. 9, 2017 /PRNewswire/ -- Amplyx Pharmaceuticals, a company developing novel antimicrobial agents for life-threatening fungal infections, today announced that it presented results from two Phase 1 studies of APX001, plus new nonclinical...

07:00
HOLON, Israel, Oct. 9, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, disclosed new data demonstrating the potential of CGEN-15032 as a...

04:05
NOTTINGHAM, England, October 9, 2017 /PRNewswire/ -- Hard water damages our protective skin barrier and could contribute to the development of skin conditions, a new study has shown from the University of Sheffield and King's College London....

02:00
LONDON, October 9, 2017 /PRNewswire/ -- Researchers from the UCL Cancer Institute and the specialist healthcare company BTG plc (LSE: BTG) have begun the first clinical trial of an experimental treatment for liver cancer using X-ray imageable...


6 octobre 2017

14:02
SAN DIEGO, Oct. 6, 2017 /PRNewswire/ -- Janssen Pharmaceutica, NV announced results from the pivotal Phase 3 EMERALD study which were published today online in The Lancet HIV and will be presented at IDWeek 2017 in San Diego. The study met its...

13:00
INDIANAPOLIS, Oct. 6, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that interim results from the double-blind, placebo-controlled Phase 3 MONARCH 3 study evaluating VerzenioTM (abemaciclib), a cyclin-dependent kinase (CDK)4...

10:52
SILVER SPRING, Md., Oct. 6, 2017 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to boost the...

09:00
LA JOLLA, Calif., Oct. 6, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), in a poster presentation at the Alliance for Regenerative Medicine's Cell and Gene Meeting on the Mesa, provided data which support the peripheral intravenous...

08:30
TAMPA, Fla., Oct. 6, 2017 /PRNewswire/ -- Intezyne Technologies, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that it closed an oversubscribed $10M Series A Preferred round lead by existing investor...

08:28
GAITHERSBURG, Md., Oct. 6, 2017 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, has published results of research obtained with its research and clinical...

05:16
STOCKHOLM, Oct. 06, 2017 /PRNewswire/ -- Cantargia AB ("Cantargia") today announces that the United States Patent and Trademark Office ("USPTO") has granted the company's patent application directed to the product candidate CAN04. The antibody CAN04...


5 octobre 2017

16:30
THOUSAND OAKS, Calif., Oct. 5, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology has published positive results from the IMLYGIC® (talimogene laherparepvec) Phase 2 '264 study. The study met its primary...

16:15
RARITAN, N.J., Oct. 5, 2017 /PRNewswire/ -- Janssen Research & Development, LLC and its development partner Bayer today announced the Phase III NAVIGATE ESUS study, evaluating the efficacy and safety of XARELTO® (rivaroxaban) for the secondary...

16:05
GERMANTOWN, Maryland and HILDEN, Germany, October 5, 2017 /PRNewswire/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of QuantiFERON®-TB Gold Plus (QFT®-Plus), the fourth generation of its leading blood test...

13:00
SAN FRANCISCO, Oct. 5, 2017 /PRNewswire/ -- goBalto, Inc., the leading provider of cloud-based clinical study startup (SSU) solutions, announced today the successful conclusion of its inaugural, invitation only, Pharmaceutical Executive Exchange...

11:41
HOBOKEN, N.J., Oct. 5, 2017 /PRNewswire/ -- According to the CDC, osteoarthritis is the most common joint disorder in the United States, affecting over 30 million Americans. A new peer-reviewed, published study shows that the polyphenols found in the...

1 2 3 4 5 6 7 8 9 10 11 12 13